Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322830 | 0.88 | ALDH1A1 (0.50) | ALDH1A1HRH3HTTRAB9ASMN1; SMN2 | |
| SCHEMBL3322828 | 0.88 | ALDH1A1 (0.50) | ALDH1A1HRH3HTTRAB9ASMN1; SMN2 | |
| SCHEMBL3324843 | 0.88 | ALDH1A1 (0.50) | ALDH1A1HRH3HTTRAB9ASMN1; SMN2 | |
| SCHEMBL3325423 | 0.87 | HRH3 (0.50) | ALDH1A1HRH3 | |
| SCHEMBL3325419 | 0.87 | HRH3 (0.50) | ALDH1A1HRH3 | |
| SCHEMBL3326310 | 0.87 | HRH3 (0.50) | ALDH1A1HRH3 | |
| SCHEMBL27752283 | 0.86 | ALDH1A1 (0.49) | ALDH1A1HRH3KCNH2CNR1CNR2 | |
| SCHEMBL3325486 | 0.85 | L3MBTL1 (0.48) | ALDH1A1HRH3KCNH2CNR1CNR2 | |
| SCHEMBL3323894 | 0.84 | POLB (0.49) | ALDH1A1HRH3CNR1HTTRAB9A | |
| SCHEMBL3326510 | 0.84 | HRH3 (0.54) | ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | claimed |
| CN-101374825-A | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | claimed |
| EP-1976840-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES AND THEIR USE AS HISTAMINE H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-08 | — | — | EP | claimed |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-19 | — | — | US | claimed |
| WO-2007080140-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES AND THEIR USE AS HISTAMINE H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-19 | — | — | WO | claimed |
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| CN-101374825-A | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1976840-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES AND THEIR USE AS HISTAMINE H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2007080140-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES AND THEIR USE AS HISTAMINE H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | HRH3, HRH4, HRH1 | ALDH1A1 405/4885HRH3 1/4885KCNH2 455/4885 |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HRH3, HRH4, HRH1 | ALDH1A1 405/4885HRH3 1/4885KCNH2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.